Immunotherapy for paraneoplastic neurological disorders

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Paraneoplastic disorders may affect any part of the central or peripheral nervous systems. Although relatively uncommon, these disorders are a significant cause of severe neurological disability among cancer patients. Most, if not all, neurological paraneoplastic disorders are believed to be autoimmune diseases in which an antitumour immune response also attacks neurons that express shared neuronal tumour antigens. Affected patients often have one or more circulating antineuronal antibodies, which serve as a diagnostic marker for the paraneoplastic condition, and in some cases are the direct mediators of neuronal injury. The exact immunopathogenesis and relative contributions of humoral or cellular immune effectors for most paraneoplastic syndromes are not well understood. Some patients have a gratifying neurological response to tumour treatment and/or immunotherapy, especially if the diagnosis is made early and treatment is initiated promptly. Unfortunately, many patients are left with severe and permanent neurological deficits despite aggressive treatment. This review summarises the current understanding of the clinical immunology of paraneoplastic disorders, and outlines immunotherapy options and outcomes.

Original languageEnglish
Pages (from-to)1339-1348
Number of pages10
JournalExpert Opinion on Biological Therapy
Volume5
Issue number10
DOIs
StatePublished - Oct 2005

Fingerprint

Immunology
Neurology
Neoplasm Antigens
Nervous System Diseases
Immunotherapy
Neurons
Tumors
Antibodies
Paraneoplastic Syndromes
Peripheral Nervous System
Allergy and Immunology
Autoimmune Diseases
Neoplasms
Therapeutics
Central Nervous System
Wounds and Injuries

Keywords

  • Antineuronal antibodies
  • Autoimmune diseases
  • Paraneoplastic syndromes

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Genetics
  • Immunology

Cite this

Immunotherapy for paraneoplastic neurological disorders. / Dropcho, Edward.

In: Expert Opinion on Biological Therapy, Vol. 5, No. 10, 10.2005, p. 1339-1348.

Research output: Contribution to journalArticle

@article{ac40c43429fe43c38edec472dad5319a,
title = "Immunotherapy for paraneoplastic neurological disorders",
abstract = "Paraneoplastic disorders may affect any part of the central or peripheral nervous systems. Although relatively uncommon, these disorders are a significant cause of severe neurological disability among cancer patients. Most, if not all, neurological paraneoplastic disorders are believed to be autoimmune diseases in which an antitumour immune response also attacks neurons that express shared neuronal tumour antigens. Affected patients often have one or more circulating antineuronal antibodies, which serve as a diagnostic marker for the paraneoplastic condition, and in some cases are the direct mediators of neuronal injury. The exact immunopathogenesis and relative contributions of humoral or cellular immune effectors for most paraneoplastic syndromes are not well understood. Some patients have a gratifying neurological response to tumour treatment and/or immunotherapy, especially if the diagnosis is made early and treatment is initiated promptly. Unfortunately, many patients are left with severe and permanent neurological deficits despite aggressive treatment. This review summarises the current understanding of the clinical immunology of paraneoplastic disorders, and outlines immunotherapy options and outcomes.",
keywords = "Antineuronal antibodies, Autoimmune diseases, Paraneoplastic syndromes",
author = "Edward Dropcho",
year = "2005",
month = "10",
doi = "10.1517/14712598.5.10.1339",
language = "English",
volume = "5",
pages = "1339--1348",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Immunotherapy for paraneoplastic neurological disorders

AU - Dropcho, Edward

PY - 2005/10

Y1 - 2005/10

N2 - Paraneoplastic disorders may affect any part of the central or peripheral nervous systems. Although relatively uncommon, these disorders are a significant cause of severe neurological disability among cancer patients. Most, if not all, neurological paraneoplastic disorders are believed to be autoimmune diseases in which an antitumour immune response also attacks neurons that express shared neuronal tumour antigens. Affected patients often have one or more circulating antineuronal antibodies, which serve as a diagnostic marker for the paraneoplastic condition, and in some cases are the direct mediators of neuronal injury. The exact immunopathogenesis and relative contributions of humoral or cellular immune effectors for most paraneoplastic syndromes are not well understood. Some patients have a gratifying neurological response to tumour treatment and/or immunotherapy, especially if the diagnosis is made early and treatment is initiated promptly. Unfortunately, many patients are left with severe and permanent neurological deficits despite aggressive treatment. This review summarises the current understanding of the clinical immunology of paraneoplastic disorders, and outlines immunotherapy options and outcomes.

AB - Paraneoplastic disorders may affect any part of the central or peripheral nervous systems. Although relatively uncommon, these disorders are a significant cause of severe neurological disability among cancer patients. Most, if not all, neurological paraneoplastic disorders are believed to be autoimmune diseases in which an antitumour immune response also attacks neurons that express shared neuronal tumour antigens. Affected patients often have one or more circulating antineuronal antibodies, which serve as a diagnostic marker for the paraneoplastic condition, and in some cases are the direct mediators of neuronal injury. The exact immunopathogenesis and relative contributions of humoral or cellular immune effectors for most paraneoplastic syndromes are not well understood. Some patients have a gratifying neurological response to tumour treatment and/or immunotherapy, especially if the diagnosis is made early and treatment is initiated promptly. Unfortunately, many patients are left with severe and permanent neurological deficits despite aggressive treatment. This review summarises the current understanding of the clinical immunology of paraneoplastic disorders, and outlines immunotherapy options and outcomes.

KW - Antineuronal antibodies

KW - Autoimmune diseases

KW - Paraneoplastic syndromes

UR - http://www.scopus.com/inward/record.url?scp=27144487396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27144487396&partnerID=8YFLogxK

U2 - 10.1517/14712598.5.10.1339

DO - 10.1517/14712598.5.10.1339

M3 - Article

C2 - 16197339

AN - SCOPUS:27144487396

VL - 5

SP - 1339

EP - 1348

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 10

ER -